Abstract |
If the optimal serum 25( OH)D level for skeletal health is 30 ng/mL or greater, then vitamin D insufficiency is widespread, affecting about 75% of adults based on a recent survey of more than 20,000 Americans. However, after a comprehensive analysis of existing research studies, the Institute of Medicine recently concluded that nearly all individuals are vitamin D replete when their 25( OH)D levels are 20 ng/mL or greater. Furthermore, two recent publications challenge the belief that 25( OH)D levels greater than 30 ng/mL are optimal for bone health. In a randomized, placebo-controlled trial, high-dose, once-yearly vitamin D therapy increased the incidence of fractures and falls. The second study reported that high-dose vitamin D did not reduce levels of parathyroid hormone or bone resorption among adults with 25( OH)D levels less than 32 ng/mL at baseline. It is time to question whether serum 25( OH)D levels of 30 ng/mL or greater are necessary for all individuals.
|
Authors | Karen E Hansen |
Journal | Current rheumatology reports
(Curr Rheumatol Rep)
Vol. 13
Issue 3
Pg. 257-64
(Jun 2011)
ISSN: 1534-6307 [Electronic] United States |
PMID | 21369796
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Bone Density
(drug effects)
- Bone Resorption
(drug therapy)
- Calcium
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Fractures, Bone
(prevention & control)
- Humans
- Male
- Meta-Analysis as Topic
- Nutrition Policy
- Randomized Controlled Trials as Topic
- Vitamin D
(adverse effects, therapeutic use)
|